Author + information
- Received October 25, 2018
- Revision received December 3, 2018
- Accepted December 26, 2018
- Published online March 18, 2019.
- Lloyd W. Klein, MDa,∗ (, )
- Tanveer Rab, MDb,
- H. Vernon Anderson, MDc,
- Amir Lotfi, MDd,
- Alexander G. Truesdell, MDe,
- Peter L. Duffy, MDf,
- Frederick Welt, MDg,
- Roxana Mehran, MDh,
- Neal S. Kleiman, MDi,
- on behalf of the Workgroup on Acute Care Cardiology and the Interventional Section Leadership Council,
- American College of Cardiology
- aRush Medical College, Chicago, Illinois
- bEmory University, Atlanta, Georgia
- cUniversity of Texas Health Science Center, Houston, Texas
- dBaystate Medical Center, Springfield, Massachusetts
- eVirginia Heart & INOVA Heart and Vascular Institute, Falls Church, Virginia
- fFirstHealth of the Carolinas, Pinehurst, North Carolina
- gUniversity of Utah, Salt Lake City, Utah
- hMount Sinai Medical Center, New York, New York
- iHouston Methodist Hospital, Houston, Texas
- ↵∗Address for correspondence:
Dr. Lloyd W. Klein, 1953 North Clybourn Avenue, Suite #R-221, Chicago, Illinois 60614.
The responsibilities of the interventional cardiologist (IC) have evolved in contemporary practice to include substantial acute care clinical duties outside of the cardiac catheterization laboratory. In particular, the IC has assumed a central role in the global management of myocardial infarction and other acute coronary syndromes in the intensive care unit and beyond. These duties have expanded to include many nonprocedural tasks. The Interventional Section Leadership Council (ISLC) of the American College of Cardiology (ACC) therefore recommends: 1) these implications should be directly considered in the ACC’s future planning and policy statements concerning manpower, competence, education, and reimbursement; 2) the development of an acute care cardiology subspecialty should be undertaken; 3) steps should be taken to adjust the number of ICs primarily on the basis of optimizing procedural volume and quality; and 4) the annual number of coronary interventions performed should not solely define competence in the future, but should include the performance of acute cardiology responsibilities.
Dr. Truesdell has served as a consultant and on the Speakers Bureau for Abiomed. Dr. Welt has received research funding from Siemens; and has served on the advisory board for Medtronic. Dr. Mehran has received grants from and served as a consultant for Abbott Laboratories, Abiomed, Boston Scientific, Cardiovascular Systems, Inc, Medscape, Siemens Medical Solutions, PLx Opco, Inc./dba PLx Pharma Inc., Regeneron Pharmaceuticals Inc., Roivant Sciences, Inc., Spectranetics/Phillips/Volcano Corporation, The Medicines Company, Sanofi, AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb, CSL Behring, Eli Lilly/Daiichi-Sankyo Inc., Medtronic, Novartis Pharmaceuticals, OrbusNeich, Claret Medical, Elixir Medical, Janssen Pharmaceuticals, Osprey Medical, and Watermark Research Partners. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received October 25, 2018.
- Revision received December 3, 2018.
- Accepted December 26, 2018.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.